MONTREAL and WATERTOWN, Mass.--(BUSINESS WIRE)--Angiochem, Inc., a clinical stage biotechnology company, and the National Brain Tumor Society (NBTS), a leading U.S. non-profit organization in the brain tumor community, today announced that Angiochem has been presented with the Innovation Recognition Award from the National Brain Tumor Society for its progress in developing novel treatments for brain tumors that are capable of crossing the blood-brain barrier. The NBTS Innovation Recognition Award acknowledges catalytic research projects that will significantly move forward the field of brain tumor research.
